The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Age-related Macular Degeneration Market Research Report 2024
Synopsis
The global Age-related Macular Degeneration market was valued at US$ 7725.7 million in 2023 and is anticipated to reach US$ 11400 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
North American market for Age-related Macular Degeneration is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Age-related Macular Degeneration is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Age-related Macular Degeneration in Drugstore is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Age-related Macular Degeneration include Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Avalanche, Bausch+Lomb and Gilead Sciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Age-related Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-related Macular Degeneration.
Report Scope
The Age-related Macular Degeneration market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Age-related Macular Degeneration market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Age-related Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer HealthCare
F. Hoffmann-La Roche
Novartis
Regeneron Pharmaceuticals
Alcon
Allergan
Avalanche
Bausch+Lomb
Gilead Sciences
Iconic Therapeutics
Neurotech Pharmaceuticals
Ohr Pharmaceutical
Segment by Type
Wet AMD
Dry AMD
Segment by Application
Drugstore
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Age-related Macular Degeneration companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Age-related Macular Degeneration market was valued at US$ 7725.7 million in 2023 and is anticipated to reach US$ 11400 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
North American market for Age-related Macular Degeneration is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Age-related Macular Degeneration is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Age-related Macular Degeneration in Drugstore is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Age-related Macular Degeneration include Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Avalanche, Bausch+Lomb and Gilead Sciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Age-related Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-related Macular Degeneration.
Report Scope
The Age-related Macular Degeneration market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Age-related Macular Degeneration market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Age-related Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer HealthCare
F. Hoffmann-La Roche
Novartis
Regeneron Pharmaceuticals
Alcon
Allergan
Avalanche
Bausch+Lomb
Gilead Sciences
Iconic Therapeutics
Neurotech Pharmaceuticals
Ohr Pharmaceutical
Segment by Type
Wet AMD
Dry AMD
Segment by Application
Drugstore
Hospital
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Age-related Macular Degeneration companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Age-related Macular Degeneration Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Wet AMD
1.2.3 Dry AMD
1.3 Market by Application
1.3.1 Global Age-related Macular Degeneration Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Drugstore
1.3.3 Hospital
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Age-related Macular Degeneration Market Perspective (2019-2030)
2.2 Age-related Macular Degeneration Growth Trends by Region
2.2.1 Global Age-related Macular Degeneration Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Age-related Macular Degeneration Historic Market Size by Region (2019-2024)
2.2.3 Age-related Macular Degeneration Forecasted Market Size by Region (2025-2030)
2.3 Age-related Macular Degeneration Market Dynamics
2.3.1 Age-related Macular Degeneration Industry Trends
2.3.2 Age-related Macular Degeneration Market Drivers
2.3.3 Age-related Macular Degeneration Market Challenges
2.3.4 Age-related Macular Degeneration Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Age-related Macular Degeneration Players by Revenue
3.1.1 Global Top Age-related Macular Degeneration Players by Revenue (2019-2024)
3.1.2 Global Age-related Macular Degeneration Revenue Market Share by Players (2019-2024)
3.2 Global Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Age-related Macular Degeneration Revenue
3.4 Global Age-related Macular Degeneration Market Concentration Ratio
3.4.1 Global Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Age-related Macular Degeneration Revenue in 2023
3.5 Age-related Macular Degeneration Key Players Head office and Area Served
3.6 Key Players Age-related Macular Degeneration Product Solution and Service
3.7 Date of Enter into Age-related Macular Degeneration Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Age-related Macular Degeneration Breakdown Data by Type
4.1 Global Age-related Macular Degeneration Historic Market Size by Type (2019-2024)
4.2 Global Age-related Macular Degeneration Forecasted Market Size by Type (2025-2030)
5 Age-related Macular Degeneration Breakdown Data by Application
5.1 Global Age-related Macular Degeneration Historic Market Size by Application (2019-2024)
5.2 Global Age-related Macular Degeneration Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Age-related Macular Degeneration Market Size (2019-2030)
6.2 North America Age-related Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Age-related Macular Degeneration Market Size by Country (2019-2024)
6.4 North America Age-related Macular Degeneration Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Age-related Macular Degeneration Market Size (2019-2030)
7.2 Europe Age-related Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Age-related Macular Degeneration Market Size by Country (2019-2024)
7.4 Europe Age-related Macular Degeneration Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Age-related Macular Degeneration Market Size (2019-2030)
8.2 Asia-Pacific Age-related Macular Degeneration Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Age-related Macular Degeneration Market Size by Region (2019-2024)
8.4 Asia-Pacific Age-related Macular Degeneration Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Age-related Macular Degeneration Market Size (2019-2030)
9.2 Latin America Age-related Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Age-related Macular Degeneration Market Size by Country (2019-2024)
9.4 Latin America Age-related Macular Degeneration Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Age-related Macular Degeneration Market Size (2019-2030)
10.2 Middle East & Africa Age-related Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Age-related Macular Degeneration Market Size by Country (2019-2024)
10.4 Middle East & Africa Age-related Macular Degeneration Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer HealthCare
11.1.1 Bayer HealthCare Company Detail
11.1.2 Bayer HealthCare Business Overview
11.1.3 Bayer HealthCare Age-related Macular Degeneration Introduction
11.1.4 Bayer HealthCare Revenue in Age-related Macular Degeneration Business (2019-2024)
11.1.5 Bayer HealthCare Recent Development
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Detail
11.2.2 F. Hoffmann-La Roche Business Overview
11.2.3 F. Hoffmann-La Roche Age-related Macular Degeneration Introduction
11.2.4 F. Hoffmann-La Roche Revenue in Age-related Macular Degeneration Business (2019-2024)
11.2.5 F. Hoffmann-La Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Age-related Macular Degeneration Introduction
11.3.4 Novartis Revenue in Age-related Macular Degeneration Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Company Detail
11.4.2 Regeneron Pharmaceuticals Business Overview
11.4.3 Regeneron Pharmaceuticals Age-related Macular Degeneration Introduction
11.4.4 Regeneron Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2019-2024)
11.4.5 Regeneron Pharmaceuticals Recent Development
11.5 Alcon
11.5.1 Alcon Company Detail
11.5.2 Alcon Business Overview
11.5.3 Alcon Age-related Macular Degeneration Introduction
11.5.4 Alcon Revenue in Age-related Macular Degeneration Business (2019-2024)
11.5.5 Alcon Recent Development
11.6 Allergan
11.6.1 Allergan Company Detail
11.6.2 Allergan Business Overview
11.6.3 Allergan Age-related Macular Degeneration Introduction
11.6.4 Allergan Revenue in Age-related Macular Degeneration Business (2019-2024)
11.6.5 Allergan Recent Development
11.7 Avalanche
11.7.1 Avalanche Company Detail
11.7.2 Avalanche Business Overview
11.7.3 Avalanche Age-related Macular Degeneration Introduction
11.7.4 Avalanche Revenue in Age-related Macular Degeneration Business (2019-2024)
11.7.5 Avalanche Recent Development
11.8 Bausch+Lomb
11.8.1 Bausch+Lomb Company Detail
11.8.2 Bausch+Lomb Business Overview
11.8.3 Bausch+Lomb Age-related Macular Degeneration Introduction
11.8.4 Bausch+Lomb Revenue in Age-related Macular Degeneration Business (2019-2024)
11.8.5 Bausch+Lomb Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Detail
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Age-related Macular Degeneration Introduction
11.9.4 Gilead Sciences Revenue in Age-related Macular Degeneration Business (2019-2024)
11.9.5 Gilead Sciences Recent Development
11.10 Iconic Therapeutics
11.10.1 Iconic Therapeutics Company Detail
11.10.2 Iconic Therapeutics Business Overview
11.10.3 Iconic Therapeutics Age-related Macular Degeneration Introduction
11.10.4 Iconic Therapeutics Revenue in Age-related Macular Degeneration Business (2019-2024)
11.10.5 Iconic Therapeutics Recent Development
11.11 Neurotech Pharmaceuticals
11.11.1 Neurotech Pharmaceuticals Company Detail
11.11.2 Neurotech Pharmaceuticals Business Overview
11.11.3 Neurotech Pharmaceuticals Age-related Macular Degeneration Introduction
11.11.4 Neurotech Pharmaceuticals Revenue in Age-related Macular Degeneration Business (2019-2024)
11.11.5 Neurotech Pharmaceuticals Recent Development
11.12 Ohr Pharmaceutical
11.12.1 Ohr Pharmaceutical Company Detail
11.12.2 Ohr Pharmaceutical Business Overview
11.12.3 Ohr Pharmaceutical Age-related Macular Degeneration Introduction
11.12.4 Ohr Pharmaceutical Revenue in Age-related Macular Degeneration Business (2019-2024)
11.12.5 Ohr Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
